Characterization of hepatic carnitine palmitoyltransferase. Use of bromoacyl derivatives and antibodies

P. S. Brady, A. K. Dunker, L. J. Brady

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Carnitine palmitoyltransferase (CPT) is a mitochondrial-inner-membrane enzyme, with activities located on both the outer and inner sides of the membrane. The inhibition of CPT by bromopalmitate derivatives was studied in intact hepatic mitochondria (representing CPT-A activity, the outer enzyme), in inverted submitochondrial vesicles (representing CPT-B, the inner enzyme), and in purified hepatic CPT. Bromopalmitoyl-CoA had an I50 (concentration giving 50% inhibition of CPT activity) of 0.63 ± 0.08 μM in intact mitochondria and 2.44 ± 0.86 μM in inverted vesicles. Preincubation of mitochondria with bromopalmitoyl-CoA decreased V(max.) for both CPT-A and CPT-B. Sonication decreased sensitivity to bromopalmitoyl-CoA, and solubilization with Triton abolished sensitivity at the concentrations used (0-10 μM). Purified CPT had a bromopalmitoyl-CoA I50 of 353 μM in aqueous buffer, 67 μM in 20% dimethyl sulphoxide, 45 μM in phosphatidylcholine liposomes and 26 μM in cardiolipin liposomes. Increasing [carnitine] at constant bromopalmitoyl-CoA concentrations or increasing [bromopalmitoyl-CoA] in the preincubation resulted in increased inhibition of purified CPT. 2-Tetradecylglycidyl-CoA and malonyl-CoA did not offer measurable protection against bromopalmitoyl-CoA inhibition of the purified CPT, suggesting a different site of interaction of bromopalmitoyl-CoA with CPT. The data suggest that the sensitivity of CPT to bromopalmitoyl-CoA may be modulated by membrane environment and assay conditions.

Original languageEnglish (US)
Pages (from-to)751-757
Number of pages7
JournalBiochemical Journal
Volume241
Issue number3
DOIs
StatePublished - Jan 1 1987

Fingerprint

Carnitine O-Palmitoyltransferase
Coenzyme A
Derivatives
Antibodies
Liver
Mitochondria
Membranes
Liposomes
Enzymes
Malonyl Coenzyme A
Sonication
Cardiolipins
Carnitine
Mitochondrial Membranes
Dimethyl Sulfoxide
Phosphatidylcholines

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Characterization of hepatic carnitine palmitoyltransferase. Use of bromoacyl derivatives and antibodies. / Brady, P. S.; Dunker, A. K.; Brady, L. J.

In: Biochemical Journal, Vol. 241, No. 3, 01.01.1987, p. 751-757.

Research output: Contribution to journalArticle

@article{2356f108f2eb439a95919f23b27001a8,
title = "Characterization of hepatic carnitine palmitoyltransferase. Use of bromoacyl derivatives and antibodies",
abstract = "Carnitine palmitoyltransferase (CPT) is a mitochondrial-inner-membrane enzyme, with activities located on both the outer and inner sides of the membrane. The inhibition of CPT by bromopalmitate derivatives was studied in intact hepatic mitochondria (representing CPT-A activity, the outer enzyme), in inverted submitochondrial vesicles (representing CPT-B, the inner enzyme), and in purified hepatic CPT. Bromopalmitoyl-CoA had an I50 (concentration giving 50{\%} inhibition of CPT activity) of 0.63 ± 0.08 μM in intact mitochondria and 2.44 ± 0.86 μM in inverted vesicles. Preincubation of mitochondria with bromopalmitoyl-CoA decreased V(max.) for both CPT-A and CPT-B. Sonication decreased sensitivity to bromopalmitoyl-CoA, and solubilization with Triton abolished sensitivity at the concentrations used (0-10 μM). Purified CPT had a bromopalmitoyl-CoA I50 of 353 μM in aqueous buffer, 67 μM in 20{\%} dimethyl sulphoxide, 45 μM in phosphatidylcholine liposomes and 26 μM in cardiolipin liposomes. Increasing [carnitine] at constant bromopalmitoyl-CoA concentrations or increasing [bromopalmitoyl-CoA] in the preincubation resulted in increased inhibition of purified CPT. 2-Tetradecylglycidyl-CoA and malonyl-CoA did not offer measurable protection against bromopalmitoyl-CoA inhibition of the purified CPT, suggesting a different site of interaction of bromopalmitoyl-CoA with CPT. The data suggest that the sensitivity of CPT to bromopalmitoyl-CoA may be modulated by membrane environment and assay conditions.",
author = "Brady, {P. S.} and Dunker, {A. K.} and Brady, {L. J.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1042/bj2410751",
language = "English (US)",
volume = "241",
pages = "751--757",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Characterization of hepatic carnitine palmitoyltransferase. Use of bromoacyl derivatives and antibodies

AU - Brady, P. S.

AU - Dunker, A. K.

AU - Brady, L. J.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Carnitine palmitoyltransferase (CPT) is a mitochondrial-inner-membrane enzyme, with activities located on both the outer and inner sides of the membrane. The inhibition of CPT by bromopalmitate derivatives was studied in intact hepatic mitochondria (representing CPT-A activity, the outer enzyme), in inverted submitochondrial vesicles (representing CPT-B, the inner enzyme), and in purified hepatic CPT. Bromopalmitoyl-CoA had an I50 (concentration giving 50% inhibition of CPT activity) of 0.63 ± 0.08 μM in intact mitochondria and 2.44 ± 0.86 μM in inverted vesicles. Preincubation of mitochondria with bromopalmitoyl-CoA decreased V(max.) for both CPT-A and CPT-B. Sonication decreased sensitivity to bromopalmitoyl-CoA, and solubilization with Triton abolished sensitivity at the concentrations used (0-10 μM). Purified CPT had a bromopalmitoyl-CoA I50 of 353 μM in aqueous buffer, 67 μM in 20% dimethyl sulphoxide, 45 μM in phosphatidylcholine liposomes and 26 μM in cardiolipin liposomes. Increasing [carnitine] at constant bromopalmitoyl-CoA concentrations or increasing [bromopalmitoyl-CoA] in the preincubation resulted in increased inhibition of purified CPT. 2-Tetradecylglycidyl-CoA and malonyl-CoA did not offer measurable protection against bromopalmitoyl-CoA inhibition of the purified CPT, suggesting a different site of interaction of bromopalmitoyl-CoA with CPT. The data suggest that the sensitivity of CPT to bromopalmitoyl-CoA may be modulated by membrane environment and assay conditions.

AB - Carnitine palmitoyltransferase (CPT) is a mitochondrial-inner-membrane enzyme, with activities located on both the outer and inner sides of the membrane. The inhibition of CPT by bromopalmitate derivatives was studied in intact hepatic mitochondria (representing CPT-A activity, the outer enzyme), in inverted submitochondrial vesicles (representing CPT-B, the inner enzyme), and in purified hepatic CPT. Bromopalmitoyl-CoA had an I50 (concentration giving 50% inhibition of CPT activity) of 0.63 ± 0.08 μM in intact mitochondria and 2.44 ± 0.86 μM in inverted vesicles. Preincubation of mitochondria with bromopalmitoyl-CoA decreased V(max.) for both CPT-A and CPT-B. Sonication decreased sensitivity to bromopalmitoyl-CoA, and solubilization with Triton abolished sensitivity at the concentrations used (0-10 μM). Purified CPT had a bromopalmitoyl-CoA I50 of 353 μM in aqueous buffer, 67 μM in 20% dimethyl sulphoxide, 45 μM in phosphatidylcholine liposomes and 26 μM in cardiolipin liposomes. Increasing [carnitine] at constant bromopalmitoyl-CoA concentrations or increasing [bromopalmitoyl-CoA] in the preincubation resulted in increased inhibition of purified CPT. 2-Tetradecylglycidyl-CoA and malonyl-CoA did not offer measurable protection against bromopalmitoyl-CoA inhibition of the purified CPT, suggesting a different site of interaction of bromopalmitoyl-CoA with CPT. The data suggest that the sensitivity of CPT to bromopalmitoyl-CoA may be modulated by membrane environment and assay conditions.

UR - http://www.scopus.com/inward/record.url?scp=0023094569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023094569&partnerID=8YFLogxK

U2 - 10.1042/bj2410751

DO - 10.1042/bj2410751

M3 - Article

C2 - 3593221

AN - SCOPUS:0023094569

VL - 241

SP - 751

EP - 757

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 3

ER -